Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
NCT02265952
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
9
Enrollment
INDUSTRY
Sponsor class
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
DRUG:
REGN1500 250 mg SC/15 mg/kg IV/450 mg SC
Sponsor
Regeneron Pharmaceuticals